PLX Share Price Performance
US$2.73
0.99 (56.90%)
75.2% undervalued intrinsic discount
US$11.00
Fair Value
Price US$2.73
AnalystConsensusTarget US$11.00
RedCandleRx US$4.23
Fair ValueUS$11.00
Share Pricen/a
Protalix BioTherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 86 Fair Values set on narratives written by author
PLX Community Narratives
AN
Fair Value
·Fair Value US$11 75.2% undervalued intrinsic discount
EMA Reviews And Rare Disease Trends Will Open Global Markets
3users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
RE
Fair Value
·Fair Value US$4.23 35.5% undervalued intrinsic discount
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Protalix BioTherapeutics
35.5% undervalued intrinsic discount
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
View narrativeRE
Updated 19 May 2025
Protalix BioTherapeutics
75.2% undervalued intrinsic discount
EMA Reviews And Rare Disease Trends Will Open Global Markets
View narrativeAN
Updated 25 Jun
Trending Discussion
No trending discussion available.
Recently Updated Narratives
RE
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
Fair Value: US$4.23 35.5% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PLX: Maintained Fair Value And 2026 Revenue Mix Will Support Upside
Fair Value: US$11 75.2% undervalued intrinsic discount
32 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Protalix BioTherapeutics, Inc. Key Details
About PLX
- Founded
- n/a
- Employees
- 226
- CEO
- WebsiteView website
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
